hi all,
I have relapsed after my second asct but the paraprotein levels remain low 3.9 and now they say they will not treat until it reaches 10 (was 5 in the past ??) I have had ctd vcd before first asct and Rd before second asct .
I was looking at the above trial as being superior to the daratumumab monotherapy I am offered , which I suspect is only given as such in the uk ( triple therapy elsewhere in the world hence lowest myeloma survival rates in Europe ).
However the Sheffield team enquired on my behalf and found that the trial have stopped recruiting in uk (Manchester and stoke is nearby) .Is anyone on this trial .?
michael ashton
docmike
Dr Michael g Ashton MBChB FRCP
